ALNY

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Alnylam Faces Securities Investigation Following $200M Revenue Guidance Cut

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Bragar Eagel &amp; Squire has opened an investigation into Alnylam after the company cut its 2026 TTR revenue guidance by about $200 million following Q2 results, triggering a sharp intraday stock decline of up to 28%. The move introduces near-term uncertainty around ALNY&#039;s compliance and valuation, with potential liabilities from investor claims. Settlement outcomes or additional legal developments could influence ALNY&#039;s stock path over weeks to months.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Bragar Eagel &amp; Squire investigating ALNY for potential securities-law claims.</li><li>ALNY cut 2026 TTR net product revenue guidance by about $200 million.</li><li>Q2 2026 results triggered intraday stock drop up to 28%.</li><li>Investors with losses invited to discuss claims; no cost.</li><li>Investigation adds near-term uncertainty to ALNY&#039;s compliance and valuation.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Alnylam Pharmaceuticals, Inc. (ALNY)</strong>: Subject of an ongoing securities-law investigation; potential impact on stock valuation and investor sentiment.</li><li><strong>Bragar Eagel &amp; Squire, P.C. (N/A)</strong>: Plaintiff law firm leading the investigation; not a market participant but relevant as the driver of the news.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This is a Legal category update tied to a securities-law investigation of ALNY, likely to affect near-term volatility and investor perception despite no immediate cash impact.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ALNY stock volatility may spike on ongoing legal proceedings and earnings commentary.</li><li>The $200M TTR revenue cut weighs on ALNY&#039;s valuation and forward multiples.</li><li>Any updates on the lawsuit or settlements could trigger rapid price moves.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>July 30, 2026: ALNY Q2 2026 results; lowered TTR net product revenue guidance by about $200 million.</li><li>Intraday drop: up to $81.25 per share, or 28.35%.</li><li>Bragar Eagel &amp; Squire investigating ALNY for possible federal securities-law violations on behalf of stockholders.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term downside risk for ALNY on ongoing legal scrutiny; monitor for settlement updates in weeks.</p>
  </section>
</section>


<article>
  <p>
    Bragar Eagel &amp; Squire, P.C., a nationally recognized stockholder rights law firm, is investigating Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of Alnylam stockholders to determine whether the company violated federal securities laws or engaged in other unlawful business practices. The investigation follows Alnylam’s July 30, 2026 quarterly results and subsequent market reaction.
  </p>

  <section>
    <h2>What’s Happening: Regulatory Investigation into ALNY</h2>
    <ul>
      <li>
        Bragar Eagel &amp; Squire, P.C., is investigating potential claims against Alnylam Pharmaceuticals, Inc. (<strong>ALNY</strong>) on behalf of Alnylam stockholders. Our investigation concerns whether Alnylam has violated the federal securities laws and/or engaged in other unlawful business practices.
      </li>
    </ul>
  </section>

  <section>
    <h2>Investigation Details: July 30, 2026 Q2 Results and Guidance Cut</h2>
    <p>
      On July 30, 2026, Alnylam announced second-quarter 2026 financial results. Among other things, the Company reported it has
      <em>“lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.”</em> As a result, Alnylam lowered its total projected TTR net product revenues by approximately <strong>$200 million</strong>. Following this news, Alnylam's stock price dropped as much as <strong>$81.25</strong> per share, or <strong>28.35%</strong>, during intraday trading on July 30, 2026.
    </p>
  </section>

  <section>
    <h2>Next Steps for Shareholders</h2>
    <ul>
      <li>
        If you purchased or otherwise acquired Alnylam shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at
        <strong>investigations@bespc.com</strong>, by telephone at (212) 355-4648, or by filling out the contact form available at
        <a href="#" rel="nofollow" target="_blank">https://bespc.com/cases/ALNY</a>. There is no cost or obligation to you.
      </li>
    </ul>
  </section>

  <section>
    <h2>About Bragar Eagel &amp; Squire, P.C.</h2>
    <p>
      Bragar Eagel &amp; Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit
      <strong>www.bespc.com</strong>. Attorney advertising. Prior results do not guarantee similar outcomes.
    </p>
  </section>

  <section>
    <h2>Contact Information</h2>
    <p>
      Bragar Eagel &amp; Squire, P.C. <br>
      Brandon Walker, Esq. <br>
      Melissa Fortunato, Esq. <br>
      (212) 355-4648 <br>
      investigations@bespc.com <br>
      www.bespc.com
    </p>
  </section>
</article>

Bragar Eagel & Squire has opened an investigation into Alnylam after the company cut its 2026 TTR revenue guidance by about $200 million following Q2 results, triggering a sharp intraday stock decline of up to 28%. The move introduces near-term uncertainty around ALNY's compliance and valuation, with potential liabilities from investor claims. Settlement outcomes or additional legal developments could influence ALNY's stock path over weeks to months.

alnylam-investigation-alert-bragar-eagel-squire-p-c-is-investigating-alnylam-pharmaceuticals-inc-on-behalf-of-alnylam-stockholders-and-encourages-investors-to-contact-the-firm

News insight

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

AI summary

Sentiment rationale

Key facts

Legal